, Registre français des traitements de suppléance de l'insuffisance rénale chronique, Agence de la Biomédecine, 2017.

M. Blüher, Obesity: global epidemiology and pathogenesis, Nat Rev Endocrinol, vol.15, issue.5, pp.288-298, 2019.

J. S. Gill, E. Hendren, and J. Dong, Differential association of body mass index with access to kidney transplantation in men and women, clin j am soc nephrol, vol.9, issue.5, pp.951-959, 2014.

N. Krishnan, R. Higgins, and A. Short, Kidney transplantation significantly improves patient and graft survival irrespective of BMI: A cohort study, Am J Transplant, vol.15, issue.9, pp.2378-2386, 2015.

M. Lassalle, L. K. Fezeu, and C. Couchoud, Obesity and access to kidney transplantation in patients starting dialysis: A prospective cohort study, PLoS ONE, vol.12, issue.5, p.176616, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01604887

M. Tran, C. E. Foster, and K. Kalantar-zadeh, Kidney transplantation in obese patients, World J Transplant, vol.6, issue.1, pp.135-143, 2016.

J. A. Lafranca, J. N. Ijzermans, and M. G. Betjes, Erratum: Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis, BMC Med, pp.13-141, 2015.

B. Nicoletto, N. K. Fonseca, and R. Manfro, Effects of Obesity on Kidney Transplantation Outcomes: A Systematic Review and Meta-Analysis. Transplantation, vol.98, issue.2, pp.167-176, 2014.

J. S. Gill, J. Lan, and J. Dong, The Survival Benefit of Kidney Transplantation in Obese Patients, Am J Transplant, vol.13, issue.8, pp.2083-2090, 2013.

K. L. Hardinger, D. L. Bohl, and M. A. Schnitzler, A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients, Transplantation, vol.80, issue.1, pp.41-46, 2005.

C. E. Staatz and S. E. Tett, Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation, Clin Pharmacokinet, vol.43, issue.10, pp.623-653, 2004.

L. M. Andrews, Y. Li, and B. Winter, Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients, Expert Opin Drug Metab Toxicol, vol.13, issue.12, pp.1225-1236, 2017.

A. D. Mayer, J. Dmitrewski, and J. P. Squifflet, Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European tacrolimus multicenter renal study group, Transplantation, vol.64, issue.3, pp.436-443, 1997.

C. Metalidis, E. Lerut, and M. Naesens, Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity, Transplantation, vol.91, issue.10, pp.1098-1102, 2011.

P. Veroux, M. Veroux, and C. Puliatti, Tacrolimus-induced neurotoxicity in kidney transplant recipients, Transplant Proc, vol.34, issue.8, pp.3188-3190, 2002.

R. Satterthwaite, S. Aswad, and V. Sunga, Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine, Transplantation, vol.65, issue.3, pp.446-449, 1998.

D. H. Peters, A. Fitton, and G. L. Plosker, A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation, Drugs, vol.46, issue.4, pp.746-794, 1993.

A. Barry and M. Levine, A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients, Ther Drug Monit, vol.32, issue.6, pp.708-714, 2010.

L. M. Andrews, D. A. Hesselink, and . Schaik-rhn-van, A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients, Br J Clin Pharmacol, vol.85, issue.3, pp.601-615, 2019.

K. A. Birdwell, B. Decker, and J. M. Barbarino, Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing, Clin Pharmacol Ther, vol.98, issue.1, pp.19-24, 2015.

T. Shimada, A. Terada, and K. Yokogawa, Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy, Transplantation, vol.74, issue.10, pp.1419-1424, 2002.

E. Størset, N. Holford, and K. Midtvedt, Importance of hematocrit for a tacrolimus target concentration strategy, Eur J Clin Pharmacol, vol.70, issue.1, pp.65-77, 2014.

E. Størset, N. Holford, and S. Hennig, Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling, Br J Clin Pharmacol, vol.78, issue.3, pp.509-523, 2014.

R. Jain, S. M. Chung, and L. Jain, Implications of obesity for drug therapy: limitations and challenges, Clin Pharmacol Ther, vol.90, issue.1, pp.77-89, 2011.

K. Sawamoto, T. T. Huong, and N. Sugimoto, Mechanisms of lower maintenance dose of tacrolimus in obese patients, Drug Metab Pharmacokinet, vol.29, issue.4, pp.341-347, 2014.

E. Rodrigo, M. A. De-cos, and B. Sánchez, High initial blood levels of tacrolimus in overweight renal transplant recipients, Transplant Proc, vol.37, issue.3, pp.1453-1454, 2005.

L. M. Andrews, B. De-winter, and J. Tang, Overweight kidney transplant recipients are at risk of being overdosed following standard bodyweight-based tacrolimus starting dose, Transplant Direct, vol.3, issue.2, p.129, 2017.

L. A. Bauer, W. A. Edwards, and E. P. Dellinger, Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients, Eur J Clin Pharmacol, vol.24, issue.5, pp.643-647, 1983.

B. J. Devine, Gentamicin therapy, Drug Intell Clin Pharm, vol.8, pp.650-655, 1974.

G. Cheymol, Effects of obesity on pharmacokinetics implications for drug therapy, Clin Pharmacokinet, vol.39, issue.3, pp.215-231, 2000.

S. M. Flechner, M. E. Kolbeinsson, and J. Tam, The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients, Transplantation, vol.47, issue.5, pp.806-810, 1989.

L. Orofino, J. Pascual, and C. Quereda, Influence of overweight on survival of kidney transplant, Nephrol Dial Transplant, vol.12, issue.4, p.855, 1997.

P. Stratta, M. Quaglia, and T. Cena, The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation, Eur J Clin Pharmacol, vol.68, issue.5, pp.671-680, 2012.

S. S. Han, D. H. Kim, and S. M. Lee, Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants, Kidney Res Clin Pract, vol.31, issue.3, pp.157-162, 2012.

K. Krzy?owska, A. Kolonko, and P. Giza, Which kidney transplant recipients can benefit from the initial tacrolimus dose reduction?, Biomed Res Int, p.4573452, 2018.

M. Brill, A. Van-rongen, and A. Houwink, Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers, Clin Pharmacokinet, vol.53, issue.10, pp.931-941, 2014.

S. K. Fried, D. A. Bunkin, and A. S. Greenberg, Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid, J Clin Endocrinol Metab, vol.83, issue.3, pp.847-850, 1998.

P. A. Kern, M. Saghizadeh, and J. M. Ong, The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase, J Clin Invest, vol.95, issue.5, pp.2111-2119, 1995.

M. Ulvestad, I. B. Skottheim, and G. S. Jakobsen, Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects, Clin Pharmacol Ther, vol.93, issue.3, pp.275-282, 2013.

R. Zini, P. Riant, and J. Barré, Disease-induced variations in plasma protein levels, Clin Pharmacokinet, vol.19, issue.3, pp.218-229, 1990.

K. Iwasaki, T. Shiraga, and H. Matsuda, Absorption, distribution and excretion of tacrolimus (FK506) in the baboon, Drug Metab Pharmacokinet, vol.13, issue.5, pp.478-483, 1998.

K. Iwasaki, T. Shiraga, and H. Matsuda, Absorption, distribution, metabolism and excretion of tacrolimus (FK506) in the Rat, Drug Metab Pharmacokinet, vol.13, issue.3, pp.259-265, 1998.

M. Brill, J. Diepstraten, and A. Van-rongen, Impact of obesity on drug metabolism and elimination in adults and children, Clin Pharmacokinet, vol.51, issue.5, pp.277-304, 2012.

Y. Caraco, E. Zylber-katz, and E. M. Berry, Significant weight reduction in obese subjects enhances carbamazepine elimination, Clin Pharmacol Ther, vol.51, issue.5, pp.501-506, 1992.

E. Thervet, M. A. Loriot, and S. Barbier, Optimization of initial tacrolimus dose using pharmacogenetic testing, Clin Pharmacol Ther, vol.87, issue.6, pp.721-726, 2010.

C. Passey, A. K. Birnbaum, and R. C. Brundage, Dosing equation for tacrolimus using genetic variants and clinical factors, Br J Clin Pharmacol, vol.72, issue.6, pp.948-957, 2011.

N. Han, H. Yun, and J. Hong, Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients, Eur J Clin Pharmacol, vol.69, issue.1, pp.53-63, 2013.

S. Chen, J. Li, and F. Meng, Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study, Clin Transplant, vol.27, issue.3, pp.272-281, 2013.

F. Andreu, H. Colom, and L. Elens, A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: A population approach, Clin Pharmacokinet, vol.56, issue.8, pp.963-975, 2017.

T. K. Bergmann, S. Hennig, and K. A. Barraclough, Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose, Ther Drug Monit, vol.36, issue.1, pp.62-70, 2014.

D. Mafra, F. Guebre-egziabher, and D. Fouque, Body mass index, muscle and fat in chronic kidney disease: questions about survival, Nephrol Dial Transplant, vol.23, issue.8, pp.2461-2466, 2008.

D. Anglicheau, M. Flamant, and M. H. Schlageter, Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation, Nephrol Dial Transplant, vol.18, issue.11, pp.2409-2414, 2003.

C. Manzanares, Therapeutic drug monitoring of tacrolimus: a moving matter, Therapie, vol.57, issue.2, pp.133-136, 2002.

J. F. Trotter, J. C. Osborne, and M. Heller, REFERENCES 1. Rapport annuel REIN 2017, Registre français des traitements de suppléance de l'insuffisance rénale chronique, Agence de la Biomédecine, Aliment Pharmacol Ther, vol.22, issue.1, pp.37-44, 2005.

M. Tran, C. E. Foster, K. Kalantar-zadeh, and H. Ichii, Kidney transplantation in obese patients, World J Transplant, vol.6, issue.1, pp.135-143, 2016.

J. A. Lafranca, J. Ijzermans, M. Betjes, and F. Dor, Erratum: Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis, BMC Med, vol.13, p.141, 2015.

B. Nicoletto, N. K. Fonseca, R. Manfro, L. F. Gonçalves, C. Leitão et al., Effects of Obesity on Kidney Transplantation Outcomes: A Systematic Review and Meta-Analysis, Transplantation, vol.98, issue.2, pp.167-176, 2014.

J. S. Gill, J. Lan, and J. Dong, The Survival Benefit of Kidney Transplantation in Obese Patients, American Journal of Transplantation, vol.13, issue.8, pp.2083-2090, 2013.

N. Krishnan, R. Higgins, and A. Short, Kidney Transplantation Significantly Improves Patient and Graft Survival Irrespective of BMI: A Cohort Study, Am J Transplant, vol.15, issue.9, pp.2378-2386, 2015.

K. L. Hardinger, D. L. Bohl, M. A. Schnitzler, M. Lockwood, G. A. Storch et al., A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients, Transplantation, vol.80, issue.1, pp.41-46, 2005.

A. D. Mayer, J. Dmitrewski, and J. P. Squifflet, Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group, Transplantation, vol.64, issue.3, pp.436-443, 1997.

C. Metalidis, E. Lerut, M. Naesens, and D. Kuypers, Expression of CYP3A5 and Pglycoprotein in Renal Allografts With Histological Signs of Calcineurin Inhibitor Nephrotoxicity, Transplantation, vol.91, issue.10, p.1098, 2011.

P. Veroux, M. Veroux, and C. Puliatti, Tacrolimus-induced neurotoxicity in kidney transplant recipients, Transplant Proc, vol.34, issue.8, pp.3188-3190, 2002.

C. E. Staatz and S. E. Tett, Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation, Clin Pharmacokinet, vol.43, issue.10, pp.623-653, 2004.

D. H. Peters, A. Fitton, G. L. Plosker, and F. D. Tacrolimus, A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation, Drugs, vol.46, issue.4, pp.746-794, 1993.

A. Barry and M. Levine, A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients, Ther Drug Monit, vol.32, issue.6, pp.708-714, 2010.

K. Sawamoto, T. T. Huong, N. Sugimoto, Y. Mizutani, Y. Sai et al., Mechanisms of lower maintenance dose of tacrolimus in obese patients, Drug Metab Pharmacokinet, vol.29, issue.4, pp.341-347, 2014.

E. Rodrigo, M. A. De-cos, and B. Sánchez, High initial blood levels of tacrolimus in overweight renal transplant recipients, Transplant Proc, vol.37, issue.3, pp.1453-1454, 2005.

L. M. Andrews, B. De-winter, and J. Tang, Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose, Transplant Direct, vol.3, issue.2, 2017.

D. J. Cohen, L. S. Martin, L. L. Christensen, R. D. Bloom, and R. S. Sung, Kidney and Pancreas Transplantation in the United States, American Journal of Transplantation, vol.6, issue.5p2, pp.1153-1169, 1995.

B. Samstein, Choosing between immunity and tolerance after transplantation, Cellular Immunology, vol.248, issue.1, pp.44-47, 2007.

W. Land, Innate alloimmunity: history and current knowledge, Exp Clin Transplant, vol.5, issue.1, pp.575-584, 2007.

C. Brick, O. Atouf, N. Benseffaj, and M. Essakalli, Rejet de la greffe rénale : mécanisme et prévention, Néphrologie & Thérapeutique, vol.7, issue.1, pp.18-26, 2011.

Q. Mao, P. I. Terasaki, J. Cai, N. El-awar, and L. Rebellato, Analysis of HLA class I specific antibodies in patients with failed allografts, Transplantation, vol.83, issue.1, pp.54-61, 2007.

J. Cai and P. I. Terasaki, Humoral theory of transplantation: mechanism, prevention, and treatment, Hum Immunol, vol.66, issue.4, pp.334-342, 2005.

R. Marks and J. Finke, Biologics in the prevention and treatment of graft rejection, Springer Semin Immunopathol, vol.27, issue.4, pp.457-476, 2006.

T. Kino, H. Hatanaka, and M. Hashimoto, FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics, J Antibiot, vol.40, issue.9, pp.1249-1255, 1987.

T. Kino, H. Hatanaka, and S. Miyata, FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro, J Antibiot, vol.40, issue.9, pp.1256-1265, 1987.

A. Azarfar, Y. Ravanshad, and H. Mehrad-majd, Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: An updated systematic review and meta-analysis, Saudi Journal of Kidney Diseases and Transplantation, vol.29, issue.6, p.1376, 2018.

L. Penninga, C. H. Møller, F. Gustafsson, D. A. Steinbrüchel, and C. Gluud, Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials, Eur J Clin Pharmacol, vol.66, issue.12, pp.1177-1187, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00627922

W. M. Flanagan, B. Corthésy, R. J. Bram, and G. R. Crabtree, Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A, Nature, vol.352, issue.6338, pp.803-807, 1991.

N. A. Clipstone and G. R. Crabtree, Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation, Nature, vol.357, issue.6380, pp.695-697, 1992.

S. J. O'keefe, J. Tamura, R. L. Kincaid, M. J. Tocci, O. Neill et al., FK-506-and CsA-sensitive activation of the interleukin-2 promoter by calcineurin, Nature, vol.357, issue.6380, pp.692-694, 1992.

P. F. Halloran, Immunosuppressive drugs for kidney transplantation, N Engl J Med, vol.351, issue.26, pp.2715-2729, 2004.

R. Venkataramanan, A. Swaminathan, and T. Prasad, Clinical pharmacokinetics of tacrolimus, Clin Pharmacokinet, vol.29, issue.6, pp.404-430, 1995.

J. J. Curtis, P. Jones, and R. Barbeito, Large within-day variation in cyclosporine absorption: circadian variation or food effect?, Clin J Am Soc Nephrol, vol.1, issue.3, pp.462-466, 2006.

W. J. Jusko, W. Piekoszewski, and G. B. Klintmalm, Pharmacokinetics of tacrolimus in liver transplant patients, Clin Pharmacol Ther, vol.57, issue.3, pp.281-290, 1995.

K. Iwasaki, T. Shiraga, and H. Matsuda, Absorption, Distribution, Metabolism and Excretion of Tacrolimus(FK506) in the Rat, Drug Metabolism and Pharmacokinetics, vol.13, issue.3, pp.259-265, 1998.

D. A. Hesselink, R. Bouamar, L. Elens, R. Van-schaik, and T. Van-gelder, The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation, Clin Pharmacokinet, vol.53, issue.2, pp.123-139, 2014.

I. R. Dubbelboer, A. Pohanka, R. Said, S. Rosenborg, and O. Beck, Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC-ESI-MS/MS, Ther Drug Monit, vol.34, issue.2, pp.134-142, 2012.

K. Iwasaki, Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics, Drug Metab Pharmacokinet, vol.22, issue.5, pp.328-335, 2007.

A. Möller, K. Iwasaki, and A. Kawamura, The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects, Drug Metab Dispos, vol.27, issue.6, pp.633-636, 1999.

L. C. Floren, I. Bekersky, and L. Z. Benet, Tacrolimus oral bioavailability doubles with coadministration of ketoconazole, Clin Pharmacol Ther, vol.62, issue.1, pp.41-49, 1997.

R. Y. Chenhsu, C. C. Loong, M. H. Chou, M. F. Lin, and W. C. Yang, Renal allograft dysfunction associated with rifampin-tacrolimus interaction, Ann Pharmacother, vol.34, issue.1, pp.27-31, 2000.

S. Yigitaslan, K. Erol, and C. Cengelli, The Effect of P-Glycoprotein Inhibition and Activation on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats, Adv Clin Exp Med, vol.25, issue.2, pp.237-242, 2016.

P. B. Watkins, S. A. Wrighton, E. G. Schuetz, D. T. Molowa, and P. S. Guzelian, Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, J Clin Invest, vol.80, issue.4, pp.1029-1036, 1987.

S. Lam, N. Partovi, L. Ting, and M. Ensom, Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?, Ann Pharmacother, vol.42, issue.7, pp.1037-1047, 2008.

D. A. Hesselink, H. Ngyuen, and M. Wabbijn, Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids, Br J Clin Pharmacol, vol.56, issue.3, pp.327-330, 2003.

D. Anglicheau, M. Flamant, and M. H. Schlageter, Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation, Nephrol Dial Transplant, vol.18, issue.11, pp.2409-2414, 2003.

T. Niwa, N. Murayama, C. Emoto, and H. Yamazaki, Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5, Curr Drug Metab, vol.9, issue.1, pp.20-33, 2008.

D. J. Mcconn, Y. S. Lin, K. Allen, K. L. Kunze, and K. E. Thummel, Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs, Drug Metab Dispos, vol.32, issue.10, pp.1083-1091, 2004.

H. De-jonge, H. De-loor, K. Verbeke, Y. Vanrenterghem, and D. R. Kuypers, In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients, Clin Pharmacol Ther, vol.92, issue.3, pp.366-375, 2012.

E. Hustert, M. Haberl, and O. Burk, The genetic determinants of the CYP3A5 polymorphism, Pharmacogenetics, vol.11, issue.9, pp.773-779, 2001.

J. K. Lamba, Y. S. Lin, E. G. Schuetz, and K. E. Thummel, Genetic contribution to variable human CYP3A-mediated metabolism, Adv Drug Deliv Rev, vol.54, issue.10, pp.1271-1294, 2002.

P. Kuehl, J. Zhang, and Y. Lin, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, vol.27, issue.4, pp.383-391, 2001.

K. A. Birdwell, B. Decker, and J. M. Barbarino, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing, Clinical Pharmacology & Therapeutics. Published, pp.19-24, 2018.

W. Shi, H. Tang, and S. Zhai, Effects of the CYP3A4*1B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis, PLoS One, vol.10, issue.6, 2015.

D. Kuypers, H. De-jonge, M. Naesens, E. Lerut, K. Verbeke et al., CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients, Clin Pharmacol Ther, vol.82, issue.6, pp.711-725, 2007.

D. A. Hesselink, R. Van-schaik, and I. P. Van-der-heiden, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clin Pharmacol Ther, vol.74, issue.3, pp.245-254, 2003.

D. Wang and W. Sadee, CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing, Pharmacogenet Genomics, vol.26, issue.1, pp.40-43, 2016.

L. Elens, R. H. Van-schaik, and N. Panin, Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenomics, vol.12, issue.10, pp.1383-1396, 2011.

V. Gijsen, R. H. Van-schaik, and L. Elens, CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients, Pharmacogenomics, vol.14, issue.9, pp.1027-1036, 2013.

L. M. Andrews, D. A. Hesselink, and . Schaik-rhn-van, A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients, British Journal of Clinical Pharmacology, vol.85, issue.3, pp.601-615, 2019.

A. N. Werk, S. Lefeldt, and H. Bruckmueller, Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance, Clin Pharmacol Ther, vol.95, issue.4, pp.416-422, 2014.

K. S. Lown, R. R. Mayo, and A. B. Leichtman, Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine, Clin Pharmacol Ther, vol.62, issue.3, pp.248-260, 1997.

E. G. Schuetz, K. N. Furuya, and J. D. Schuetz, Interindividual variation in expression of Pglycoprotein in normal human liver and secondary hepatic neoplasms, J Pharmacol Exp Ther, vol.275, issue.2, pp.1011-1018, 1995.

A. Okyar, S. A. Kumar, and E. Filipski, Sex-, feeding-, and circadian time-dependency of P-glycoprotein expression and activity -implications for mechanistic pharmacokinetics modeling, Sci Rep, vol.9, issue.1, p.10505, 2019.

R. Vafadari, R. Bouamar, and D. A. Hesselink, Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus, Ther Drug Monit, vol.35, issue.4, pp.459-465, 2013.

N. Shuker, R. Bouamar, W. Weimar, R. Van-schaik, T. Van-gelder et al.,

, ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation, Clin Chim Acta, vol.413, pp.1326-1337, 2012.

S. N. Hart and X. Zhong, P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity, Expert Opin Drug Metab Toxicol, vol.4, issue.4, pp.439-452, 2008.

N. Huang, V. Agrawal, K. M. Giacomini, and W. L. Miller, Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations, Proc Natl Acad Sci, vol.105, issue.5, pp.1733-1738, 2008.

L. Elens, D. A. Hesselink, and R. Bouamar, Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients, Ther Drug Monit, vol.36, issue.1, pp.71-79, 2014.

I. Lunde, S. Bremer, and K. Midtvedt, The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients, Eur J Clin Pharmacol, vol.70, issue.6, pp.685-693, 2014.

J. Zhang, H. Zhang, X. Ding, S. Ma, and L. Miao, Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers, Eur J Clin Pharmacol, vol.69, issue.4, pp.807-812, 2013.

J. T. Tang, L. M. Andrews, and . Gelder-t-van, Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations, Expert Opinion on Drug Metabolism & Toxicology, vol.12, issue.5, pp.555-565, 2016.

K. Klein, M. Thomas, and S. Winter, PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo, Clin Pharmacol Ther, vol.91, issue.6, pp.1044-1052, 2012.

F. Krenzien, A. Elkhal, and M. Quante, A Rationale for Age-Adapted Immunosuppression in Organ Transplantation, Transplantation, vol.99, issue.11, pp.2258-2268, 2015.

Y. Shi, D. A. Hesselink, and T. Van-gelder, Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients, Transplant Rev (Orlando), vol.29, issue.4, pp.224-230, 2015.

J. George, K. Byth, and G. C. Farrell, Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver, Biochem Pharmacol, vol.50, issue.5, pp.727-730, 1995.

W. E. Fitzsimmons, I. Bekersky, D. Dressler, R. K. Hodosh, E. Mekki et al., Demographic considerations in tacrolimus pharmacokinetics, Transplant Proc, vol.30, issue.4, pp.1359-1364, 1998.

D. Kuypers, K. Claes, and P. Evenepoel, Time-related clinical determinants of longterm tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients, Clin Pharmacokinet, vol.43, issue.11, pp.741-762, 2004.

B. Meibohm, I. Beierle, and H. Derendorf, How important are gender differences in pharmacokinetics?, Clin Pharmacokinet, vol.41, issue.5, pp.329-342, 2002.

J. T. Tang, L. M. Andrews, and . Gelder-t-van, Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations, Expert Opinion on Drug Metabolism & Toxicology, vol.12, issue.5, pp.555-565, 2016.

H. Xie, A. Wood, R. B. Kim, C. M. Stein, and G. R. Wilkinson, Genetic variability in CYP3A5 and its possible consequences, Pharmacogenomics, vol.5, issue.3, pp.243-272, 2004.

Y. Liu, H. Hao, C. Liu, G. Wang, and H. Xie, Drugs as CYP3A Probes, Inducers, and Inhibitors, Drug Metabolism Reviews, vol.39, issue.4, pp.699-721, 2007.

J. Mcgraw and D. Waller, Cytochrome P450 variations in different ethnic populations, Expert Opinion on Drug Metabolism & Toxicology, vol.8, issue.3, pp.371-382, 2012.

L. Elens, R. Bouamar, and D. A. Hesselink, A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients, Clin Chem, vol.57, issue.11, pp.1574-1583, 2011.

D. Wang, Y. Guo, S. A. Wrighton, G. E. Cooke, and W. Sadee, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, Pharmacogenomics J, vol.11, issue.4, pp.274-286, 2011.

M. Scheiner, A. M. Damasceno, and R. C. Maia, ABCB1 single nucleotide polymorphisms in the Brazilian population, Mol Biol Rep, vol.37, issue.1, pp.111-118, 2010.

C. Manzanares, Therapeutic drug monitoring of tacrolimus: a moving matter, Therapie, vol.57, issue.2, pp.133-136, 2002.

J. F. Trotter, J. C. Osborne, M. Heller, and U. Christians, Effect of hepatitis C infection on tacrolimus doses and blood levels in liver transplantation recipients, Aliment Pharmacol Ther, vol.22, issue.1, pp.37-44, 2005.

J. R. Lee, T. Muthukumar, and D. Dadhania, Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation, PLOS ONE, vol.10, issue.3, p.122399, 2015.

S. R. Lieber and M. L. Volk, Non-adherence and graft failure in adult liver transplant recipients, Dig Dis Sci, vol.58, issue.3, pp.824-834, 2013.

H. M. Gallagher, G. Sarwar, and T. Tse, Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival, J Heart Lung Transplant, vol.34, issue.11, pp.1442-1448, 2015.

L. Borra, J. I. Roodnat, J. A. Kal, R. Mathot, W. Weimar et al., High withinpatient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation, Nephrol Dial Transplant, vol.25, issue.8, pp.2757-2763, 2010.

T. Vanhove, T. Vermeulen, P. Annaert, E. Lerut, and D. Kuypers, High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients, American Journal of Transplantation, vol.16, issue.10, pp.2954-2963, 2016.

A. Hart, J. M. Smith, and M. A. Skeans, Annual Data Report: Kidney, 2017.

, Am J Transplant, vol.19, issue.2, pp.19-123, 2019.

S. S. Farouk and J. L. Rein, The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? Advances in Chronic Kidney Disease, vol.27, pp.56-66, 2020.

G. N. De-graav, S. Bergan, C. C. Baan, W. Weimar, T. Van-gelder et al.,

, Therapeutic Drug Monitoring of Belatacept in Kidney Transplantation, Ther Drug Monit, vol.37, issue.5, pp.560-567, 2015.

G. Gupta, A. Regmi, and D. Kumar, Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction, American Journal of Transplantation, vol.15, issue.10, pp.2726-2731, 2015.

J. P. Bantle, K. A. Nath, D. Sutherland, J. S. Najarian, and T. F. Ferris, Effects of Cyclosporine on the Renin-Angiotensin-Aldosterone System and Potassium Excretion in Renal Transplant Recipients, Arch Intern Med, vol.145, issue.3, pp.505-508, 1985.

A. S. Terker, C. Zhang, and J. A. Mccormick, Potassium Modulates Electrolyte Balance and Blood Pressure through Effects on Distal Cell Voltage and Chloride, Cell Metabolism, vol.21, issue.1, pp.39-50, 2015.

E. J. Hoorn, S. B. Walsh, and J. A. Mccormick, The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension, Nat Med, vol.17, issue.10, pp.1304-1309, 2011.

J. P. Lea, J. M. Sands, S. J. Mcmahon, and J. A. Tumlin, Evidence that the inhibition of Na+/K+-ATPase activity by FK506 involves calcineurin, Kidney International, vol.46, issue.3, pp.647-652, 1994.

T. Nijenhuis, J. Hoenderop, and R. Bindels, Downregulation of Ca2+ and Mg2+ Transport Proteins in the Kidney Explains Tacrolimus (FK506)-Induced Hypercalciuria and Hypomagnesemia, JASN, vol.15, issue.3, pp.549-557, 2004.

W. Nl and D. Jh, Cyclosporin-induced hypomagnesaemia and renal magnesium wasting in rats, Clin Sci (Lond), vol.75, issue.5, pp.509-514, 1988.

K. Numakura, S. Satoh, and N. Tsuchiya, Hyperuricemia at 1 Year After Renal Transplantation, Its Prevalence, Associated Factors, and Graft Survival, Transplantation, vol.94, issue.2, pp.145-151, 2012.

A. A. Awan, J. Niu, and J. S. Pan, Trends in the Causes of Death among Kidney Transplant Recipients in the United States (1996-2014), Am J Nephrol, vol.48, issue.6, pp.472-481, 2018.

K. Madsen, U. G. Friis, and J. L. Gooch, Inhibition of calcineurin phosphatase promotes exocytosis of renin from juxtaglomerular cells, Kidney International, vol.77, issue.2, pp.110-117, 2010.

B. Akman, M. Uyar, B. Afsar, S. Sezer, F. N. Ozdemir et al., Lipid Profile During Azathioprine or Mycophenolate Mofetil Combinations With Cyclosporine and Steroids, Transplantation Proceedings, vol.39, issue.1, pp.135-137, 2007.

C. M. Ballantyne, E. J. Podet, and W. P. Patsch, Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels, JAMA, vol.262, issue.1, pp.53-56, 1989.

R. Tory, K. Sachs-barrable, J. S. Hill, and K. M. Wasan, Cyclosporine A and Rapamycin induce in vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma, International Journal of Pharmaceutics, vol.358, issue.1, pp.219-223, 2008.

A. C. Webster, R. R. Taylor, J. R. Chapman, and J. C. Craig, Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients, Cochrane Database of Systematic Reviews, issue.4, 2005.

K. Tamura, T. Fujimura, and T. Tsutsumi, Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell, Transplantation, vol.59, issue.11, pp.1606-1613, 1995.

J. D. Pirsch, J. Miller, M. H. Deierhoi, F. Vincenti, and R. S. Filo, A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation1, Transplantation, vol.63, issue.7, pp.977-983, 1997.

W. O. Bechstein, Neurotoxicity of calcineurin inhibitors: impact and clinical management, Transplant International, vol.13, issue.5, pp.313-326, 2000.

E. Wijdicks, Neurotoxicity of immunosuppressive drugs, Liver Transplantation, vol.7, issue.11, pp.937-942, 2001.

A. Gafter-gvili, B. Sredni, R. Gal, U. Gafter, and Y. Kalechman, Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes, American Journal of Physiology-Cell Physiology, vol.284, issue.6, pp.1593-1603, 2003.

L. Tricot, C. Lebbé, E. Pillebout, F. Martinez, C. Legendre et al., Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients, Transplantation, vol.80, issue.11, pp.1546-1549, 2005.

H. De-jonge, M. Naesens, and D. Kuypers, New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation, Ther Drug Monit, vol.31, issue.4, pp.416-435, 2009.

, Association internationale de surveillance thérapeutique des médicaments et de toxicologie clinique, 2020.

H. Ekberg, C. Bernasconi, and H. Tedesco-silva, Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation, Am J Transplant, vol.9, issue.8, pp.1876-1885, 2009.

M. Brunet, T. Van-gelder, and A. Åsberg, Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report, Therapeutic Drug Monitoring, vol.41, issue.3, pp.261-307, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02150345

H. Lemmens, D. P. Bernstein, and J. B. Brodsky, Estimating blood volume in obese and morbidly obese patients, Obes Surg, vol.16, issue.6, pp.773-776, 2006.

M. F. Herrera and M. Deitel, Cardiac function in massively obese patients and the effect of weight loss, Can J Surg, vol.34, issue.5, pp.431-434, 1991.

J. K. Alexander, E. W. Dennis, W. G. Smith, K. H. Amad, W. C. Duncan et al., Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity, Cardiovasc Res Cent Bull, vol.1, pp.39-44, 1962.

D. W. Crocker, Lipomatous infiltrates of the heart, Arch Pathol Lab Med, vol.102, issue.2, pp.69-72, 1978.

S. Bharati and M. Lev, Cardiac conduction system involvement in sudden death of obese young people, Am Heart J, vol.129, issue.2, pp.273-281, 1995.

R. L. Jones and M. Nzekwu, The effects of body mass index on lung volumes, Chest, vol.130, issue.3, pp.827-833, 2006.

R. Rajala, M. Partinen, T. Sane, R. Pelkonen, K. Huikuri et al., Obstructive sleep apnoea syndrome in morbidly obese patients, J Intern Med, vol.230, issue.2, pp.125-129, 1991.

G. Guzzaloni, G. Grugni, A. Minocci, D. Moro, and F. Morabito, Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test, Int J Obes Relat Metab Disord, vol.24, issue.6, pp.772-776, 2000.

A. Casati and M. Putzu, Anesthesia in the obese patient: pharmacokinetic considerations, J Clin Anesth, vol.17, issue.2, pp.134-145, 2005.

M. Kotlyar and S. W. Carson, Effects of obesity on the cytochrome P450 enzyme system, Int J Clin Pharmacol Ther, vol.37, issue.1, pp.8-19, 1999.

P. Anastasio, L. Spitali, and A. Frangiosa, Glomerular filtration rate in severely overweight normotensive humans, Am J Kidney Dis, vol.35, issue.6, pp.1144-1148, 2000.

S. Janmahasatian, S. B. Duffull, A. Chagnac, C. Kirkpatrick, and B. Green, Lean body mass normalizes the effect of obesity on renal function, British Journal of Clinical Pharmacology, vol.65, issue.6, pp.964-965, 2008.

P. G. Schmitz, M. P. O'donnell, B. L. Kasiske, S. A. Katz, and W. F. Keane, Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril, Am J Physiol, vol.263, issue.3, pp.496-502, 1992.

B. L. Kasiske, M. P. Cleary, O. Donnell, M. P. Keane, and W. F. , Effects of genetic obesity on renal structure and function in the Zucker rat, J Lab Clin Med, vol.106, issue.5, pp.598-604, 1985.

A. Cardoso-júnior, L. Coelho, and P. R. Savassi-rocha, Gastric emptying of solids and semi-solids in morbidly obese and non-obese subjects: an assessment using the 13C-octanoic acid and 13C-acetic acid breath tests, Obes Surg, vol.17, issue.2, pp.236-241, 2007.

T. Teixeira, N. Souza, and P. G. Chiarello, Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors, Clin Nutr, vol.31, issue.5, pp.735-740, 2012.

J. Xing and J. Chen, Alterations of gastrointestinal motility in obesity, Obes Res, vol.12, issue.11, pp.1723-1732, 2004.

S. J. French, B. Murray, R. D. Rumsey, C. P. Sepple, and N. W. Read, Preliminary studies on the gastrointestinal responses to fatty meals in obese people, Int J Obes Relat Metab Disord, vol.17, issue.5, pp.295-300, 1993.

O. Wisén and C. Johansson, Gastrointestinal function in obesity: motility, secretion, and absorption following a liquid test meal, Metab Clin Exp, vol.41, issue.4, pp.390-395, 1992.

K. J. Wolf and R. G. Lorenz, Gut Microbiota and Obesity, Curr Obes Rep, vol.1, issue.1, pp.1-8, 2012.

R. A. Blouin, J. H. Kolpek, and H. J. Mann, Influence of obesity on drug disposition, Clin Pharm, vol.6, issue.9, pp.706-714, 1987.

S. L. Bowman, S. A. Hudson, G. Simpson, J. F. Munro, and J. A. Clements, A comparison of the pharmacokinetics of propranolol in obese and normal volunteers, Br J Clin Pharmacol, vol.21, issue.5, pp.529-532, 1986.

D. J. Greenblatt, H. Friedman, and E. S. Burstein, Trazodone kinetics: effect of age, gender, and obesity, Clin Pharmacol Ther, vol.42, issue.2, pp.193-200, 1987.

D. J. Greenblatt, D. R. Abernethy, A. Locniskar, J. S. Harmatz, R. A. Limjuco et al., Effect of age, gender, and obesity on midazolam kinetics, Anesthesiology, vol.61, issue.1, pp.27-35, 1984.

M. G. Kees, S. Weber, F. Kees, and T. Horbach, Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients, J Antimicrob Chemother, vol.66, issue.10, pp.2330-2335, 2011.

S. M. Flechner, M. E. Kolbeinsson, J. Tam, and B. Lum, The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients, Transplantation, vol.47, issue.5, pp.806-810, 1989.

G. Cheymol, J. Weissenburger, J. M. Poirier, and C. Gellee, The pharmacokinetics of dexfenfluramine in obese and non-obese subjects, Br J Clin Pharmacol, vol.39, issue.6, pp.684-687, 1995.

M. Brill, A. Van-rongen, and A. Houwink, Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers, Clin Pharmacokinet, vol.53, issue.10, pp.931-941, 2014.

C. Lloret-linares and L. Hachon, Adaptation posologique chez le sujet obèse, Réanimation, vol.24, issue.4, pp.367-378, 2015.

A. Boulamery-velly, N. Simon, and B. Bruguerolle, Particularités pharmacocinétiques chez le patient obèse, Réanimation, vol.15, issue.6, pp.427-432, 2006.

R. Jain, S. Chung, and L. Jain, Implications of Obesity for Drug Therapy: Limitations and Challenges, Clinical Pharmacology & Therapeutics, vol.90, issue.1, pp.77-89, 2011.

S. Van-kralingen, J. Diepstraten, and M. Peeters, Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients, Clin Pharmacokinet, vol.50, issue.11, pp.739-750, 2011.

J. Diepstraten, V. Chidambaran, and S. Sadhasivam, An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children, CPT Pharmacometrics Syst Pharmacol, vol.2, p.73, 2013.

C. Knibbe, M. Brill, A. Van-rongen, J. Diepstraten, P. H. Van-der-graaf et al., Drug Disposition in Obesity: Toward Evidence-Based Dosing, Annual Review of Pharmacology and Toxicology, vol.55, issue.1, pp.149-167, 2015.

M. Brill, A. Houwink, and S. Schmidt, Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis, J Antimicrob Chemother, vol.69, issue.3, pp.715-723, 2014.

S. Van-kralingen, M. Taks, and J. Diepstraten, Pharmacokinetics and protein binding of cefazolin in morbidly obese patients, Eur J Clin Pharmacol, vol.67, issue.10, pp.985-992, 2011.

J. Diepstraten, C. M. Hackeng, and S. Van-kralingen, Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients, OBES SURG, vol.22, issue.5, pp.791-796, 2012.

H. Lemmens, D. P. Bernstein, and J. B. Brodsky, Estimating blood volume in obese and morbidly obese patients, Obes Surg, vol.16, issue.6, pp.773-776, 2006.

S. Van-kralingen, E. Van-de-garde, and C. Knibbe, Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients, Br J Clin Pharmacol, vol.71, issue.1, pp.34-40, 2011.

D. R. Abernethy, D. J. Greenblatt, M. Divoll, and R. I. Shader, Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen, J Lab Clin Med, vol.101, issue.6, pp.873-880, 1983.

M. J. Hanley, D. R. Abernethy, and D. J. Greenblatt, Effect of obesity on the pharmacokinetics of drugs in humans, Clin Pharmacokinet, vol.49, issue.2, pp.71-87, 2010.

M. Brill, J. Diepstraten, A. Van-rongen, S. Van-kralingen, J. N. Van-den-anker et al., Impact of obesity on drug metabolism and elimination in adults and children, Clin Pharmacokinet, vol.51, issue.5, pp.277-304, 2012.

L. A. Bauer, D. J. Black, and J. S. Lill, Vancomycin dosing in morbidly obese patients, Eur J Clin Pharmacol, vol.54, issue.8, pp.621-625, 1998.

P. T. Daley-yates and D. C. Mcbrien, The mechanism of renal clearance of cisplatin (cisdichlorodiammine platinum ii) and its modification by furosemide and probenecid, Biochem Pharmacol, vol.31, issue.13, pp.2243-2246, 1982.

S. Allard, M. Kinzig, G. Boivin, F. Sörgel, and M. Lebel, Intravenous ciprofloxacin disposition in obesity, Clin Pharmacol Ther, vol.54, issue.4, pp.368-373, 1993.

R. S. Rivlin, Keeping the young-elderly healthy: is it too late to improve our health through nutrition?, Am J Clin Nutr, vol.86, issue.5, pp.1572-1576, 2007.

A. O. Alvarez, Morbid Obesity: Peri-Operative Management, 2004.

D. D. Bois and E. Bois, Clinical calorimetry: tenth paper a formula to estimate the approximate surface area if height and weight be known, Arch Intern Med (Chic)

. Xvii(6_2, , pp.863-871

K. M. Field, S. Kosmider, and M. Jefford, Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey, J Oncol Pract, vol.4, issue.3, pp.108-113, 2008.

B. J. Devine, Gentamicin therapy, Drug Intell Clin Pharm, vol.8, pp.650-655, 1974.

B. Green and S. B. Duffull, What is the best size descriptor to use for pharmacokinetic studies in the obese?, Br J Clin Pharmacol, vol.58, issue.2, pp.119-133, 2004.

B. Green and S. Duffull, Caution when lean body weight is used as a size descriptor for obese subjects, Clin Pharmacol Ther, vol.72, issue.6, pp.743-744, 2002.

S. Janmahasatian, S. B. Duffull, S. Ash, L. C. Ward, N. M. Byrne et al., Quantification of lean bodyweight, Clin Pharmacokinet, vol.44, issue.10, pp.1051-1065, 2005.

L. A. Bauer, W. A. Edwards, E. P. Dellinger, and D. A. Simonowitz, Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients, Eur J Clin Pharmacol, vol.24, issue.5, pp.643-647, 1983.

S. B. Duffull, M. J. Dooley, B. Green, S. G. Poole, and C. Kirkpatrick, A standard weight descriptor for dose adjustment in the obese patient, Clin Pharmacokinet, vol.43, issue.15, pp.1167-1178, 2004.

T. Kokuhu, K. Fukushima, H. Ushigome, N. Yoshimura, and N. Sugioka, Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, Int J Med Sci, vol.10, issue.12, pp.1665-1673, 2001.

M. Barreau, F. Saint-marcoux, J. B. Woillard, and P. Marquet, Modifications pharmacocinétiques chez les sujets obèses ou ayant bénéficié d'une chirurgie bariatrique : application aux immunosuppresseurs

M. Lassalle, L. Fezeu, C. Couchoud, T. Hannedouche, Z. A. Massy et al., Obésité et accès à la greffe rénale parmi des patients démarrant une dialyse : une étude de cohorte prospective, Néphrologie & Thérapeutique, vol.12, issue.5, p.281, 2016.

J. A. Lafranca, J. N. Ijzermans, M. G. Betjes, and F. J. Dor, Erratum: Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis, BMC Med, vol.13, 2015.

L. Orofino, J. Pascual, C. Quereda, J. Burgos, R. Marcen et al., Influence of overweight on survival of kidney transplant, Nephrol Dial Transplant, vol.12, issue.4, p.855, 1997.

L. Hortal, A. Fernandez, and A. Losada, Study of the cyclosporine concentration at 2 hours in stable renal transplant patients and relation to body mass index, Transplantation Proceedings, vol.33, issue.7-8, pp.3110-3111, 2001.

P. Stratta, M. Quaglia, and T. Cena, The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation, Eur J Clin Pharmacol, vol.68, issue.5, pp.671-680, 2012.

S. S. Han, D. H. Kim, and S. M. Lee, Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants., Pharmacokinetics of tacrolimus according to body composition in recipients of kidney transplants, Kidney Res Clin Pract, vol.31, pp.157-162, 2012.

M. Ulvestad, I. B. Skottheim, and G. S. Jakobsen, Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects, Clin Pharmacol Ther, vol.93, issue.3, pp.275-282, 2013.

L. M. Andrews, Y. Li, and B. Winter, Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients, Expert Opinion on Drug Metabolism & Toxicology, vol.13, issue.12, pp.1225-1236, 2017.

Y. Miyamoto, T. Uno, and H. Yamamoto, Pharmacokinetic and immunosuppressive effects of tacrolimus-loaded biodegradable microspheres, Liver Transpl, vol.10, issue.3, pp.392-396, 2004.

K. Krzy?owska, A. Kolonko, P. Giza, J. Chudek, and A. Wi?cek, Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?

K. Krzy?owska, A. Kolonko, P. Giza, J. Chudek, and A. Wi?cek, No Significant Influence of Reduced Initial Tacrolimus Dose on Risk of Underdosing and Early Graft Function in Older and Overweight Kidney Transplant Recipients, Transplantation Proceedings, vol.50, issue.6, pp.1755-1759, 2018.

N. M. Jasiak-panek, E. Wenzler, and S. Patel, A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients, Clinical Transplantation, vol.0, issue.0, p.13640